Clinical trial
Multiple Reaction Monitoring (MRM) Versus I 125 Radioimmunoassay (RIA) for the Quantification of Orexin-A/Hypocretin-1 Levels in Cerebrospinal Fluid: a Prospective Diagnostic Validation Study in Patients With Hypersomnolence
NCT05615584 is registered in ClinicalTrials.gov with University Hospital, Montpellier as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multiple Reaction Monitoring (MRM) Versus I 125 Radioimmunoassay (RIA) for the Quantification of Orexin-A/Hypocretin-1 Levels in Cerebrospinal Fluid: a Prospective Diagnostic Validation Study in Patients With Hypersomnolence
- Lead sponsor
- University Hospital, Montpellier
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- February 15, 2023
- Completion date
- October 9, 2024
- Enrollment
- 117 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.